JCB, Volume 10, Number 2, 2003 Editorial Vol.10 No. 2 (2003) Editorial John M Sime   Article Vol.10 No. 2 (2003) Pharmacoeconomics and its role in the growth of the biotechnology industry Thomas D Szucs Assuming a constant stream of new biotechnology products in the future, three key issues are likely to influence the growth of the biotechnology industry in an increasi Article Vol.10 No. 2 (2003) Business development: A barometer of future success Edmund L Valentine In the pharmaceutical and biotechnology industry, an excellent barometer of potential future success is a company's ability to find and execute accreditive deals. The k Article Vol.10 No. 2 (2003) Understanding 'science and the public' Jane Gregory Public acceptance of the products of biotechnology is an important issue for the industry. This paper looks at relevant academic and policy developments in the field of Article Vol.10 No. 2 (2003) Revised CIOMS International Ethical Guidelines for Biomedical Research Jane Gregory The revised CIOMS 2002 International Ethical Guidelines for Biomedical Research Involving Human Subjects supersede the previous 1993 Guidelines and consist of a stateme Article Vol.10 No. 2 (2003) ScanBalt BioRegion: A model case for Europe Wolfgang Blank Europe takes part in a global competition for scientists, capital and knowledge – major factors of importance for societal growth. In the USA, regions such as Ba Article Vol.10 No. 2 (2003) Current and future prospects for the global biotechnology industry Faiz Kermani The number of biotechnology compounds has been increasing steadily over the past 20 years, reflecting the key contribution that biotechnology is now making to healthcar Article Vol.10 No. 2 (2003) Integra: The research tool patent revival Charles J Raubicheck There was a question as to the value of research tool patents; for instance, whether practising such patents for preclinical research would be within the research exemp Article Vol.10 No. 2 (2003) Marketspace: Leading biotechnology players, 2002–08: Key products, indications and technologies Alex K Pavlou For the full year 2002, the top ten biotechnology houses generated combined revenues (= royalties/licensing income + ethical or product sales; product sales includes bo Legal and Regulatory Updates Vol.10 No. 2 (2003) Legal and regulatory update John Wilkinson   Legal and Regulatory Updates Vol.10 No. 2 (2003) EU Financial accounts reports David Citron  Â
